Abcam plc
Abcam plc (ABCZF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
abczf · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Abcam plc (ABCZF) measures how much investors pay for each dollar of the company's trailing earnings. ABCZF's current PE ratio of 578.45x is calculated by dividing its stock price of $22.25 by its TTM earnings per share of $0.02. +113.6% elevated vs 5Y avg 270.8x
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2006 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 17 fiscal years · Front-end computedMinQ1 · 25%47.4x
MedianQ3 · 75%803.9x
Max
At 578.45x, ABCZF's current P/E is higher than in 94% of its annual fiscal year readings over the past 17 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Abcam plcYou ABCZF | $5.1B | 578.45x | -43.3% | $0.02 |
 ALK-Abelló A/S AKABY | $0M | 543.57x | -46.7% | $1.00 |
 Alpine Immune Sciences, Inc. ALPN | $4.5B | N/A | — | -$0.64 |
 Arena Pharmaceuticals, Inc. ARNA | $0M | N/A | — | -$11.33 |
 Ascentage Pharma Group International ASPHF | $1.7B | N/A | — | -$3.40 |
 CymaBay Therapeutics, Inc. CBAY | $3.7B | N/A | — | -$0.99 |
 Churchill Capital Corp XI CCXI | $431M | 1495.64x | +46.7% | $0.01 |
Industry Average 2 peers with valid PE | — | 1019.61x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $0.00 | — | |
2023-12-31 FY2023 | — | $0.00 | — | |
2022-12-31 FY2022 | — | $-0.04 | — | |
2021-12-31 FY2021 | 803.87x | $0.02 | +291.7% | |
2021-06-30 FY2021 | 205.23x | $0.07 | -11.2% | |
2020-06-30 FY2020 | 231.22x | $0.06 | +234.9% | |
2019-06-30 FY2019 | 69.04x | $0.22 | +54.0% | |
2018-06-30 FY2018 | 44.82x | $0.30 | -5.4% | |
2017-06-30 FY2017 | 47.38x | $0.21 | +14.7% | |
2016-06-30 FY2016 | 41.29x | $0.19 | +49.4% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Abcam plc (ABCZF) measures how much investors pay for each dollar of the company's trailing earnings. ABCZF's current PE ratio of 578.45x is calculated by dividing its stock price of $22.25 by its TTM earnings per share of $0.02.
Frequently asked questions
ABCZF pe ratio · 6 questionsABCZF's current PE ratio is 578.45x as of 2026-06-08, based on a stock price of $22.25 and TTM EPS of $0.02. Data sourced from Financial Modeling Prep via ABCZF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Abcam plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08